Verona Pharma Partners with Nuance Pharma, Submits Ensifentrine NDA to US FDA for COPD Maintenance Treatment

29 June 2023 | Thursday | News

Nuance Pharma announces its partner, Verona Pharma plc (Nasdaq: VRNA), has submitted a New Drug Application ("NDA") to the US Food and Drug Administration ("FDA") for approval of ensifentrine for the maintenance treatment of patients with chronic obstructive pulmonary disease ("COPD").
Image Source : Public Domain

Image Source : Public Domain

Ensifentrine is a selective dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and non-steroidal anti-inflammatory activities in one molecule. If approved, it is expected to be the first novel mechanism available for the treatment of COPD in over 10 years.

Mr. Mark Lotter, founder and CEO of Nuance Pharma, commented: "We are immensely proud to see ensifentrine's progress with the FDA. This exciting milestone affirmed our confidence in ensifentrine's potential to re-define the COPD treatment globally. Like our partner Verona, we are highly committed to bringing this first-in-class therapy to patients in Greater China. Together, we aim to significantly improve the lives of millions coping with this challenging disease."

"Millions of symptomatic COPD patients in the US are in urgent need of new treatment options," said David Zaccardelli, Pharm. D., President and Chief Executive Officer of Verona Pharma. "The NDA submission for ensifentrine is a significant milestone towards our goal of bringing this potential first-in-class therapy to COPD patients and we look forward to working with the FDA during their review." The NDA contains data from the positive Phase 3 ENHANCE studies and other ensifentrine clinical studies including data from approximately 3,000 subjects.

In 2021, Nuance Pharma entered into an agreement with Verona Pharma for the exclusive rights to develop and commercialize ensifentrine in Greater China. On April 6th 2023, Nuance Pharma announced first patient in (FPI) for the ENHANCE-China Phase III clinical trial

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in